C
삼천당제약
000250KOSDAQ의약품 제조업44.5 / 100
Reference Date: 2026-04-13
Financial Score12.0 / 40
News Sentiment13.6 / 25
Momentum9.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, PER raises overvaluation concerns. Plunged 34.6% over the past month, and news sentiment is positive.
Company InformationBased on 2025 Annual Report
Business Overview
Samcheon Pharmaceutical, established in 1943, is a leading manufacturer and distributor of prescription pharmaceuticals, specializing in antibiotics, cardiovascular treatments, digestive system medications, and ophthalmic solutions. In 2024, its consolidated sales reached 231.8 billion won, a 9.9% increase from the previous year, with its subsidiary Optus Pharmaceuticals reporting a 6.4% rise in sales to 87.16 billion won.
Number of Employees
436people
Average Salary
65.8M KRW
Score Calculation Basis
Detailed Financial Score
PER
2234.51Industry Average 14.800.0Point
151.0x industry avg (risky)
PBR
—Industry Average 1.043.5Point
ROE
3.37Industry Average 4.422.5Point
Below industry avg
Debt Ratio
25.05Industry Average 11.980.0Point
2.1x industry avg (risky)
Trend 2023~20256.0 / 10 points
Revenue Growth Rate
2.0 / 3
Avg ▲9.7% (2-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲74.1% (2-year basis)
ROE Trend
1.0 / 4
Avg ROE 0.1% (improving, 3yr)
Detailed News Sentiment
38 totalPositive 4Neutral 29Negative 0Average Sentiment Score 54.8
- Neutral
- Neutral
- Neutral
Detailed Momentum
52-week position3.0Point
52w lower range (35%)
Current 505,000Won52-week high 1,184,00052-week low 130,900
1-month return0.0Point
1m -34.59% (strong drop)
Volume trend6.0Point
Volume surge
Detailed Disclosure
9 totalPositive 0Neutral 9Negative 0
- Neutral임원ㆍ주요주주특정증권등거래계획철회보고서2026-04-06
- Neutral투자판단관련주요경영사항 (경구용 당뇨 치료제 리벨서스 제네릭 및 경구용 비만 치료제 위고비 오럴 제네릭(세마글루타이드) 미국 라이센스 계약 체결)2026-03-30
- Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-30
- Neutral정기주주총회결과2026-03-30
- Neutral임원ㆍ주요주주특정증권등거래계획보고서2026-03-24